SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--True North Therapeutics, Inc., announced today a publication demonstrating that the company’s C1s antibody prevents the destruction of human red blood cells exposed to plasma samples of patients with a type of autoimmune hemolytic anemia (AIHA). The article entitled “TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinin disease patient autoantibodies” was published on-line in the journal Blood earlier this month. TNT003 is the murine analog of True North’s lead humanized monoclonal antibody drug candidate, TNT009, for which the company plans to initiate the first clinical program in 2015.
Help employers find you! Check out all the jobs and post your resume.
